183 related articles for article (PubMed ID: 30546938)
1. Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort.
Wang Q; Gregg JR; Gu J; Ye Y; Chang DW; Davis JW; Thompson TC; Kim J; Logothetis CJ; Wu X
Oncoimmunology; 2019; 8(1):e1483303. PubMed ID: 30546938
[TBL] [Abstract][Full Text] [Related]
2. Genetic variants in epithelial-mesenchymal transition genes as predictors of clinical outcomes in localized prostate cancer.
Deng Y; Xie K; Logothetis CJ; Thompson TC; Kim J; Huang M; Chang DW; Gu J; Wu X; Ye Y
Carcinogenesis; 2020 Aug; 41(8):1057-1064. PubMed ID: 32215555
[TBL] [Abstract][Full Text] [Related]
3. Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance.
Shu X; Ye Y; Gu J; He Y; Davis JW; Thompson TC; Logothetis CJ; Kim J; Wu X
Carcinogenesis; 2016 Oct; 37(10):965-971. PubMed ID: 27515962
[TBL] [Abstract][Full Text] [Related]
4. Associations Between iCOGS Single Nucleotide Polymorphisms and Upgrading in Both Surgical and Active Surveillance Cohorts of Men with Prostate Cancer.
Kearns JT; Lapin B; Wang E; Roehl KA; Cooper P; Catalona WJ; Helfand BT
Eur Urol; 2016 Feb; 69(2):223-8. PubMed ID: 26411806
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study.
Wang Q; Ye Y; Yu H; Lin SH; Tu H; Liang D; Chang DW; Huang M; Wu X
Cancer Immunol Immunother; 2021 Mar; 70(3):701-712. PubMed ID: 32909077
[TBL] [Abstract][Full Text] [Related]
6. Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis.
Xie W; Yang M; Chan J; Sun T; Mucci LA; Penney KL; Lee GS; Kantoff PW
Prostate; 2016 May; 76(7):691-9. PubMed ID: 26847995
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
8. Genetic predisposition to early recurrence in clinically localized prostate cancer.
Borque Á; del Amo J; Esteban LM; Ars E; Hernández C; Planas J; Arruza A; Llarena R; Palou J; Herranz F; Raventós CX; Tejedor D; Artieda M; Simon L; Martínez A; Carceller E; Suárez M; Allué M; Sanz G; Morote J
BJU Int; 2013 Apr; 111(4):549-58. PubMed ID: 22759231
[TBL] [Abstract][Full Text] [Related]
9. Association between single-nucleotide polymorphisms in DNA double-strand break repair genes and prostate cancer aggressiveness in the Spanish population.
Henríquez-Hernández LA; Valenciano A; Foro-Arnalot P; Álvarez-Cubero MJ; Cozar JM; Suárez-Novo JF; Castells-Esteve M; Fernández-Gonzalo P; De-Paula-Carranza B; Ferrer M; Guedea F; Sancho-Pardo G; Craven-Bartle J; Ortiz-Gordillo MJ; Cabrera-Roldán P; Rodríguez-Melcón JI; Herrera-Ramos E; Rodríguez-Gallego C; Lara PC
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):28-34. PubMed ID: 26754263
[TBL] [Abstract][Full Text] [Related]
10. Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance.
Ferro M; Lucarelli G; Bruzzese D; Di Lorenzo G; Perdonà S; Autorino R; Cantiello F; La Rocca R; Busetto GM; Cimmino A; Buonerba C; Battaglia M; Damiano R; De Cobelli O; Mirone V; Terracciano D
Oncotarget; 2017 Mar; 8(11):18424-18434. PubMed ID: 27793023
[TBL] [Abstract][Full Text] [Related]
11. Primary Gleason pattern upgrading in contemporary patients with D'Amico low-risk prostate cancer: implications for future biomarkers and imaging modalities.
Leyh-Bannurah SR; Abou-Haidar H; Dell'Oglio P; Schiffmann J; Tian Z; Heinzer H; Huland H; Graefen M; Budäus L; Karakiewicz PI
BJU Int; 2017 May; 119(5):692-699. PubMed ID: 27367469
[TBL] [Abstract][Full Text] [Related]
12. A proposal of a new nomogram for predicting upstaging in contemporary D'Amico low-risk prostate cancer patients.
Leyh-Bannurah SR; Dell'Oglio P; Tian Z; Schiffmann J; Shariat SF; Suardi N; Francesco M; Alberto B; Heinzer H; Huland H; Graefen M; Budäus L; Karakiewicz PI
World J Urol; 2017 Feb; 35(2):189-197. PubMed ID: 27289238
[TBL] [Abstract][Full Text] [Related]
13. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program.
Bul M; van den Bergh RC; Rannikko A; Valdagni R; Pickles T; Bangma CH; Roobol MJ
Eur Urol; 2012 Feb; 61(2):370-7. PubMed ID: 21704447
[TBL] [Abstract][Full Text] [Related]
14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
15. KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness.
Lin HY; Huang PY; Cheng CH; Tung HY; Fang Z; Berglund AE; Chen A; French-Kwawu J; Harris D; Pow-Sang J; Yamoah K; Cleveland JL; Awasthi S; Rounbehler RJ; Gerke T; Dhillon J; Eeles R; Kote-Jarai Z; Muir K; ; Schleutker J; Pashayan N; ; Neal DE; Nielsen SF; Nordestgaard BG; Gronberg H; Wiklund F; Giles GG; Haiman CA; Travis RC; Stanford JL; Kibel AS; Cybulski C; Khaw KT; Maier C; Thibodeau SN; Teixeira MR; Cannon-Albright L; Brenner H; Kaneva R; Pandha H; ; Srinivasan S; Clements J; Batra J; Park JY
Sci Rep; 2021 Apr; 11(1):9264. PubMed ID: 33927218
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
17. Impact of Gleason Pattern 5 on outcomes of patients with prostate cancer and iodine-125 prostate brachytherapy.
Makino T; Miwa S; Koshida K
Prostate Int; 2016 Dec; 4(4):152-155. PubMed ID: 27995115
[TBL] [Abstract][Full Text] [Related]
18. Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations.
Gandellini P; Casiraghi N; Rancati T; Benelli M; Doldi V; Romanel A; Colecchia M; Marenghi C; Valdagni R; Demichelis F; Zaffaroni N
Eur Urol Oncol; 2019 May; 2(3):277-285. PubMed ID: 31200842
[TBL] [Abstract][Full Text] [Related]
19. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.
Drost FH; Nieboer D; Morgan TM; Carroll PR; Roobol MJ;
Eur Urol; 2019 Nov; 76(5):693-702. PubMed ID: 31451332
[TBL] [Abstract][Full Text] [Related]
20. A prospective clinical study of the implications of IL-8 in the diagnosis, aggressiveness and prognosis of prostate cancer.
Roumeguère T; Legrand F; Rassy EE; Kaitouni MI; Albisinni S; Rousseau A; Vanhaeverbeek M; Rorive S; Decaestecker C; Debeir O; Boudjeltia KZ; Aoun F
Future Sci OA; 2018 Feb; 4(2):FSO266. PubMed ID: 29379640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
